A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 670 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Selpercatinib Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC MOST POPULAR GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... September 17, 2020 To Combat Cancer Treatment Resistance, Researchers Try Leveraging Evolution August 22, 2024 A New Online Tool Predicts RFS and OS Probabilities in Patients... February 7, 2024 Health inequalities: Why is it harder for some people to eat... June 24, 2022 Load more HOT NEWS Spring Budget 2023: What does it mean for the mission to... EMA Recommends Granting a Conditional Marketing Authorisation for Repotrectinib Cancer in My Community: Working to Eliminate the Stigma of Cancer... Long-Term Benefit of Sotorasib in Patients with Pretreated KRASG12C-Mutated NSCLC
